Patient No | Exon | Tumour cell percentage (%) | Ion torrent PGM | Scorpions-ARMS Variants | Sanger Variants | ||
---|---|---|---|---|---|---|---|

Variants | Coverage (X) | Frequency (%) | |||||

2 | 2 | 65 | p.G13D(c.38G>A) | 546 | 38.5 | p.G13D(c.38G>A) | p.G13D(c.38G>A) |

3 | 2 | 85 | p.G12D(c.35G>A) | 2110 | 49.8 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

6 | 2 | 90 | p.G12D(c.35G>A) | 640 | 28.1 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

15 | 2 | 70 | p.G12D(c.35G>A) | 609 | 23.0 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

18 | 2 | 80 | p.G12D(c.35G>A) | 369 | 50.1 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

20 | 2 | 85 | p.G12V(c.35G>T) | 820 | 56.6 | p.G12V(c.35G>T) | p.G12V(c.35G>T) |

24 | 2 | 70 | p.G12D(c.35G>A) | 1035 | 54.2 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

25 | 2 | 70 | p.G12D(c.35G>A) | 1560 | 53.4 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

34 | 2 | 80 | p.G12D(c.35G>A) | 885 | 27.9 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

35 | 2 | 65 | p.G13D(c.38G>A) | 639 | 36.3 | p.G13D(c.38G>A) | p.G13D(c.38G>A) |

37 | 2 | 90 | p.G13C(c.37G>T) | 628 | 59.1 | ND | p.G13C(c.37G>T) |

42 | 2 | 75 | p.G12D(c.35G>A) | 1580 | 22.2 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

44 | 2 | 80 | p.G12D(c.35G>A) | 1728 | 31.7 | p.G12D(c.35G>A) | p.G12D(c.35G>A) |

Bold typeface indicates the discrepant case among three methods.

CRC, colorectal cancer; FFPE, formalin-fixed paraffin-embedded; ND, mutation status could not be determined by the Therascreen kit.